Your browser is no longer supported. Please, upgrade your browser.
TRPX Therapix Biosciences Ltd. daily Stock Chart
Therapix Biosciences Ltd.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-55.28%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-33.63%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-7.85%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-71.59%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-86.95%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.25 - 4.69 Perf YTD-71.59%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-93.24% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low25.69% ATR0.13
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)34.26 Volatility18.60% 22.41%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume2.50 Prev Close0.32
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.91M Price0.32
Recom- SMA20-54.33% SMA50-39.81% SMA200-70.07% Volume0 Change0.00%
Jul-09-20 09:08AM  
Jul-01-20 07:10AM  
Jun-29-20 09:10AM  
Jun-02-20 08:00AM  
May-19-20 08:30AM  
May-07-20 06:04PM  
Apr-28-20 08:30AM  
Apr-22-20 04:30PM  
Apr-01-20 09:29AM  
Mar-25-20 09:30AM  
Mar-19-20 09:27AM  
Feb-27-20 04:01PM  
Jan-31-20 03:45PM  
Dec-04-19 08:45AM  
Dec-02-19 12:35PM  
Nov-21-19 07:22AM  
Nov-20-19 05:45PM  
Nov-19-19 12:45PM  
Nov-18-19 05:30PM  
Nov-13-19 09:30AM  
Nov-08-19 08:14AM  
Nov-07-19 05:02PM  
Oct-15-19 08:30AM  
Oct-11-19 08:14AM  
Oct-10-19 06:12PM  
Aug-27-19 09:30AM  
Jul-31-19 09:27AM  
Jul-23-19 10:25AM  
Jul-05-19 03:49AM  
Jun-18-19 09:30AM  
May-29-19 09:25AM  
May-24-19 07:44AM  
May-23-19 04:30PM  
Mar-28-19 08:36AM  
Mar-19-19 06:30AM  
Dec-23-18 07:30AM  
Dec-21-18 08:30AM  
Dec-11-18 08:30AM  
Dec-03-18 08:30AM  
Nov-29-18 04:34PM  
Nov-27-18 08:30AM  
Oct-26-18 11:25AM  
Oct-24-18 11:25AM  
Oct-23-18 08:52AM  
Oct-22-18 06:56PM  
Oct-05-18 08:10AM  
Aug-30-18 01:30PM  
Aug-20-18 08:30AM  
Jul-17-18 08:30AM  
Jul-12-18 08:30AM  
Jul-11-18 08:57AM  
Jun-27-18 08:00AM  
Jun-11-18 04:00PM  
Jun-05-18 04:30PM  
May-31-18 04:55PM  
May-15-18 08:31AM  
May-09-18 08:35AM  
Apr-11-18 08:00AM  
Apr-10-18 08:20AM  
Apr-09-18 07:18AM  
Mar-20-18 08:50AM  
Feb-07-18 08:30AM  
Jan-09-18 08:30AM  
Dec-04-17 08:38AM  
Nov-21-17 08:30AM  
Nov-10-17 08:30AM  
Nov-09-17 08:00AM  
Nov-07-17 09:00AM  
Nov-02-17 02:30PM  
Oct-30-17 10:41AM  
Oct-18-17 08:30AM  
Oct-09-17 08:10AM  
Oct-06-17 08:30AM  
Sep-28-17 08:20AM  
Sep-27-17 08:41AM  
Aug-10-17 08:00AM  
Aug-03-17 08:30AM  
Jul-11-17 09:00AM  
Jun-27-17 04:15PM  
May-30-17 08:15AM  
May-24-17 05:40PM  
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.